Michal Abraham

This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 8 EPO patents. Top assignee: Biokine Therapeutics Ltd.. Active years: 2013-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michal Abraham. Retrieved from https://idiyas.com/inventor/michal-abraham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 75.0

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 35(Granted Patents)

Location History:

Mevaseret Zion, IL (2013 - 2014)
Mevasseret Zion, IL (2014 - 2021)

Company Filing History:

8 out of 35

Biokine Therapeutics Ltd.

patents

Years Active: 2013-2021

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11129824 - Small molecules for inhibiting chemokine activity and/or cancer cells growth (2021-09-28),

2. 10646465 - Small molecules against cancer (2020-05-12),

3. 9493557 - Chemokine binding polypeptides for treating autoimmunity and inflammation (2016-11-15),

4. 9427456 - Peptide therapy for increasing platelet levels (2016-08-30),

5. 8765683 - T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy (2014-07-01),

6. 8685398 - Chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer (2014-04-01),

7. 8663651 - T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation (2014-03-04),

8. 8455450 - Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof (2013-06-04),

Title: Michal Abraham: Innovator in Cancer Research

Introduction

Michal Abraham is a prominent inventor based in Mevasseret Zion, Israel. He has made significant contributions to the field of cancer research, holding a total of 8 patents. His work focuses on developing small molecules that can inhibit chemokine activity and cancer cell growth, showcasing his commitment to advancing medical science.

Latest Patents

Abraham's latest patents include groundbreaking compounds capable of inducing the death of cancer cells and modulating the biological activity of chemokines. These compounds are designed to treat diseases and disorders associated with chemokine activity, cell migration, and kinase inhibition. His innovative formulations are represented by specific chemical formulae, which are detailed in his patent specifications. Additionally, he has developed small molecules that target cancer cells and inflammatory diseases, further emphasizing his dedication to finding effective treatments.

Career Highlights

Throughout his career, Michal Abraham has worked with notable companies in the biotechnology sector, including Biokine Therapeutics Ltd. and BioLineRx Ltd. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in cancer therapies.

Collaborations

Abraham has collaborated with esteemed colleagues such as Amnon Peled and Orly Eizenberg. These partnerships have played a crucial role in the development of his innovative compounds and have enhanced the impact of his research.

Conclusion

In summary, Michal Abraham is a dedicated inventor whose work in cancer research has led to the development of several important patents. His contributions continue to influence the field and hold promise for future medical advancements.

Profile summary based on public USPTO records.